---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-23-004924"
form_type: "8-K"
ticker: "CVM"
cik: "0000725363"
company_name: "CEL SCI CORP"
filed_at: "2023-04-19T23:59:59+00:00"
generated_at: "2026-06-17T00:00:47.567432+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# CEL-SCI to pursue Health Canada's conditional approval pathway for Multikine in head & neck cancer

## Summary
- Health Canada advised CEL-SCI to request approval under Notice of Compliance with Conditions (NOC/c) policy for Multikine.
- Plans to file drug submission for earlier access in Canada while preparing U.S. BLA and pursuing other country approvals.
- Phase 3 IT-MATTERS study in head & neck cancer showed median OS improvement of 46.5 months for lower-risk patients.
- Five-year survival: 62.7% for Multikine vs 48.6% control; tumor shrinkage >30% in ~1 of 6 patients in 3 weeks.
- 5 patients had complete tumor disappearance in 3 weeks prior to surgery.

## SEC filing metadata
- accession: 0001654954-23-004924
- form_type: 8-K
- ticker: CVM
- cik: 0000725363
- company_name: CEL SCI CORP
- filed_at: 2023-04-19T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/725363/000165495423004924/0001654954-23-004924-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/725363/000165495423004924/cvm_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-23-004924
- JSON: https://secwatch.observer/filing/0001654954-23-004924.json
- Plain text: https://secwatch.observer/filing/0001654954-23-004924.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.